Key Differences Between AOD 9604 and MOTS-C | Feature | AOD 9604 | MOTS-C | |-----------------------|-------------------------------------|----------------------------------------| | Origin | HGH fragment | Mitochondrial peptide | | Primary function | Fat metabolism and fat loss | Cellular energy regulation and metabolism | | Effects on hormones | Minimal impact on HGH and insulin | Improves insulin sensitivity | | Common goals | Weight loss, fat reduction | Energy boost, metabolic health | | Research status | Several clinical trials on fat loss | Emerging research on metabolism | These differences mean the peptides serve different purposes, even though both relate to metabolism
There is no national screening program for haemoglobinopathies within Australia and as a result there is variability in testing, but identifying vulnerable populations is important 29 (Table 3)
THE PEPTIDE COMPLEX
Bmp4 promotes a brown to white-like adipocyte shift
Mechanism difference Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine) Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine) AOD-9604: targeted fat-metabolism signaling
(2013) Vitamin B12 supplementation in treating major depressive disorder: a randomized controlled trial
